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Mucosal Pemphigus Vulgaris Anti-Dsg3 IgG Is
Pathogenic to the Oral Mucosa of Humanized
Dsg3 Mice
Donna A. Culton1, Suzanne K. McCray1, Moonhee Park1, James C. Roberts1, Ning Li1, Daniel C. Zedek1,2,3,
Grant J. Anhalt4, Dale O. Cowley5,6, Zhi Liu1 and Luis A. Diaz1
There are two major clinical subsets of pemphigus vulgaris (PV)—mucosal PV (mPV) and mucocutaneous PV
(mcPV). The mPV subset exhibits anti-human desmoglein (Dsg) 3 autoantibodies that fail to recognize murine
Dsg3 (mDsg3); thus, passive transfer experiments of mPV IgG into wild-type (WT) mice have been unsuccessful at
inducing disease. We therefore generated a fully humanized Dsg3 (hDSG3) murine model utilizing a hDsg3
transgenic animal crossed to the mDsg3 knockout line. Expression of hDsg3 in the mucosa rescues the mDsg3
knockout phenotype. Well-characterized mPV sera bind mucosal epithelia from the hDsg3 mice, but not mucosal
tissues from WT mice, as detected by indirect immunoﬂuorescence (IF). The majority of mPV sera preferentially
recognize hDsg3 compared with mDsg3 by immunoprecipitation as well. Passive transfer of mPV IgG into adult
hDsg3 mice, but not WT mice, induces suprabasilar acantholysis in mucosal tissues, thus conﬁrming the
pathogenicity of mPV anti-hDsg3 IgG in vivo. Human anti-hDsg3 antibodies are detected in perilesional mucosa
as well as in sera of recipient mice by IF. These ﬁndings suggest that the Dsg3 epitopes targeted by pathogenic
mPV IgG are human speciﬁc. This hDsg3 mouse model will be invaluable in studying the clinical transition from
mPV to mcPV.
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INTRODUCTION
Pemphigus vulgaris (PV) is an autoimmune blistering disease
affecting the skin and mucosa (Lever, 1965). Autoantibody
binding to keratinocyte adhesion proteins desmoglein (Dsg) 1
and Dsg3 leads to acantholysis with intraepidermal clefting
histologically, and blister formation clinically. Two distinct
clinical variants of PV have been described—mucosal pre-
dominant PV (mPV) and mucocutaneous PV (mcPV; Ding et al.,
1997). Patients with mPV present with disease localized to the
mucosal tissues and typically harbor autoantibodies to Dsg3.
Patients with mcPV have disease affecting both the mucosa and
skin and typically harbor autoantibodies to both Dsg3 and Dsg1
(Ding et al., 1997; Amagai et al., 1999b). Interestingly, the
clinical course of most PV patients begins with mucosal lesions
(Lever, 1965; Eversole et al., 1972; Meurer et al., 1977; Herrero-
Gonzalez et al., 2010). Following a variable period of time,
most patients will have disease progress to involve not only the
mucosa but the skin as well. Although mPV patients have
autoantibodies to Dsg3 alone, the transition from mPV to mcPV
is marked by the additional development of autoantibodies to
Dsg1 (Ding et al., 1997; Ishii et al., 1997; Miyagawa et al.,
1999; Amagai et al., 1999b). The factors that precipitate this
progression to mcPV in some patients are not known. Indeed,
not all mPV patients progress to mcPV, as ~40% of patients
remain with disease limited to the mucosa (Scully et al., 1999).
Aside from the clinical distinction between mPV and mcPV,
recent studies suggest a difference in disease course between
mPV and mcPV. Whereas early reports suggested that initial
mucosal involvement was associated with a poor prognosis,
newer ﬁndings show that the presence of initial mucosal
involvement is a prognostic factor for achieving complete
remission off treatment (Mimouni et al., 2010; Almugairen
et al., 2013). In addition, mPV patients have a lower mortality
compared with patients with mcPV (Mourellou et al., 1995;
Wolf et al., 1995), suggesting that mPV patients have an
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overall better prognosis than mcPV patients. Despite the fact
that mPV may be associated with a better outcome than
mcPV, mucosal lesions can be recalcitrant in mcPV patients
and often persist after cutaneous disease has remitted (Scully
et al., 1999). Therefore, exploring the factors involved in the
transition from mPV to mcPV and the differences in the anti-
Dsg3 autoantibodies from mPV and mcPV patients could
have important clinical implications.
Signiﬁcant progress has been made in deﬁning the
pathogenicity of autoantibodies from mcPV patients using
the passive transfer model, whereby puriﬁed IgG from mcPV
sera induces acantholysis and blister formation upon transfer
to neonatal mice (Ding et al., 1997, 1999). Unfortunately,
similar studies using mPV IgG have been hampered as
autoantibodies from mPV patients fail to recognize mucosal
or cutaneous tissues in wild-type (WT) mice, and thus fail to
induce disease in the passive transfer model (Ding et al.,
1997; Mahoney et al., 1999). To further characterize the
pathogenicity of mPV autoantibodies in an in vivo system, we
have generated a fully humanized Dsg3 (hDsg3) murine
model utilizing a hDsg3 transgenic animal crossed to the
murine Dsg3 (mDsg3) knockout line. hDsg3 is expressed
predominantly in the mucosal tissues, similar to that of mDsg3
in WT mice. We show that the majority of sera from well-
characterized mPV patients preferentially recognize hDsg3 by
indirect immunoﬂuorescence (IF) on hDsg3Tg murine muco-
sal tissues as well as by immunoprecipitation. Furthermore,
passive transfer of mPV IgG leads to IgG deposition in the
intercellular spaces (ICS) of the mucosal epithelium, mucosal
erosions, and acantholysis with suprabasilar clefting on
histology in the hDsg3Tg animals, but not WT animals. These
ﬁndings suggest that the pathogenic epitopes recognized in
mPV anti-Dsg3 autoantibodies are human speciﬁc.
RESULTS
Generation of fully hDsg3Tg mice
The hDsg3Tg line was generated via standard pronuclear
microinjection techniques using the hDsg3 bacterial artiﬁcial
chromosome (BAC) (Figure 1a). Offspring carrying the BAC
were crossed to mDsg3 knockout (KO) heterozygote mice.
Following a complex breeding strategy (Supplementary Figure
S1 online), crossing of resultant hDsg3TgmDsg3WT/KO and
hDsg3NegmDsg3WT/KO animals gave offspring of multiple geno-
types on the B6 background, including hDsg3TgmDsg3KO/KO
(fully hDsg3, here forward termed hDsg3Tg), hDsg3NegmDsg3WT/WT
(WT), and hDsg3NegmDsg3KO/KO (mDsg3KO) mice. Geno-
typing was performed on genomic DNA from tail snips using
hDsg3 BAC–speciﬁc primers as well as mDsg3 WT and KO
allele–speciﬁc primers (Figure 1b).
Expression of hDsg3 in hDsg3Tg mice
To conﬁrm the expression of the hDsg3 transgene in hDsg3Tg
mice, palatal tissue was harvested from hDsg3Tg mice and
mDsg3KO and WT littermate controls. IF was then performed
using antibodies to mDsg3 (clones AK18 and AK23) and
hDsg3 (clone 5G11). Whereas AK23 is known to have
signiﬁcant crossreactivity to hDsg3, AK18 has been reported
to have less hDsg3 crossreactivity and was therefore included
in this analysis. As shown in Figure 2a, anti-mDsg3 AK18
recognizes the ICS of the WT palate with some recognition of
the ICS of the hDsg3Tg palate, whereas anti-mDsg3 AK23
recognized the ICS of both WT and hDsg3Tg palates.
Anti-hDsg3 5G11 recognizes the ICS only in the palate of
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Figure 1. Generation of fully humanized Dsg3 Tg mice. (a) The human Dsg3
bacterial artiﬁcial chromosome (BAC) clone RP11-1123B14 (hDsg3 BAC) was
used to create the hDsg3Tg line by standard pronuclear injection technique.
(b) Following a series of crosses to the mDsg3KO line and subsequent B6
background, genotyping of the F1 and F2 offspring was performed using
hDsg3BAC as well as mDsg3WT and mDsg3KO allele–speciﬁc primers. Dsg,
desmoglein; hDsg3, human Dsg3; KO, knockout; mDsg3, murine Dsg3.
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Figure 2. hDsg3Tg mice express hDsg3 in mucosal tissues. (a) Indirect
immunoﬂuorescence using mDsg3KO, WT, and hDsg3Tg oral mucosal tissue
(palate) was performed with anti-mDsg3 mAb AK18, anti-mDsg3 mAb AK23,
and anti-hDsg3 mAb 5G11 and detected by goat anti-mIgG FITC. (b) Western
blot of mucosal tissue extracts from mDsg3KO, WT, and hDsg3Tg mice was
performed with anti-mDsg3 mAb AK18 and anti-hDsg3 mAb 5G11. Human
tissue extract is shown as a control. Bar=25 μm. Dsg, desmoglein; hDsg3,
human Dsg3; KO, knockout; mDsg3, murine Dsg3; WT, wild type.
DA Culton et al.
mPV IgG Are Pathogenic in Humanized Dsg3 Mice
www.jidonline.org 1591
the hDsg3Tg mice, conﬁrming speciﬁc expression of hDsg3 in
the hDsg3Tg palate. Expression of hDsg3 was also noted in
the buccal mucosa, tongue, esophagus, basal layer of the
skin, and hair follicles in the hDsg3Tg animals in a similar
pattern to that of mDsg3 in WT mice (data not shown). There
was no expression in the stomach, small and large intestine,
lung, heart, kidney, and liver (data not shown).
Immunoblotting of mucosal extracts from mDsg3KO, WT,
and hDsg3Tg mice was performed as a secondary method to
conﬁrm expression. Anti-mDsg3 AK23 recognizes conforma-
tional epitopes and was not included in this analysis (Tsunoda
et al., 2003). Anti-mDsg3 AK18 detects a band of approxi-
mately 130 kDa in the WT mucosal extracts, whereas anti-
hDsg3 5G11 detects a band of similar size in the hDsg3Tg
mucosal and human extracts (Figure 2b). There is no
detection of mDsg3 or hDsg3 in mDsg3KO mucosal extracts
as expected.
Thus, hDsg3 is expressed in hDsg3Tg mice in a similar
pattern to that of mDsg3 in WT mice. Furthermore, expression
of endogenous Dsg1 and desmocollin 3 (Dsc3) is similar in WT
and hDsg3Tg skin and mucosa, suggesting that introduction of
hDsg3 does not alter Dsg1 or Dsc3 expression in hDsg3Tg
mice (Figure 4a and Supplementary Figure S2 online).
Expression of hDsg3 rescues the mDsg3KO phenotype
As previously described, mDsg3KO mice show runting and
mucosal acantholysis with suprabasilar clefting histologically
(Koch et al., 1997). To investigate whether hDsg3 could
compensate for the loss of mDsg3, we examined littermates
clinically and obtained weights at 21 days of age. Fully
humanized mice (hDsg3Tg) are similar in size (Figure 3a) and
weight (Figure 3b) to WT littermates. As noted previously,
mDsg3KO mice show a more severe phenotype on the B6
background (Hata et al., 2011). Indeed, the majority of litter-
mates with the mDsg3KO genotype on the B6 background die
prior to weaning (data not shown). The lifespan of hDsg3Tg
mice is similar to that of WT littermates.
Mucosal tissue was also harvested from mDsg3KO, WT,
and hDsg3Tg littermates for routine histology. Whereas the
mDsg3KO buccal mucosa shows suprabasilar clefting with
acantholysis, hDsg3Tg mucosa shows normal histology
similar to that of WT littermates, conﬁrming that expression
of hDsg3 is sufﬁcient to rescue the mDsg3KO phenotype
(Figure 3c).
IgG from mPV sera preferentially recognizes hDsg3
The sera from well-known mPV (n=10) and mcPV (n= 10)
patients were characterized in terms of IgG and IgG4 indirect
IF titers using monkey esophagus substrate. The sera were also
tested for IgG and IgG4 reactivity to recombinant hDsg3 and
Dsg1 by ELISA. All sera tested showed reactivity to Dsg3 by
ELISA. As expected, mPV patients’ IgG and IgG4 recognize
Dsg3 without a high degree of reactivity to Dsg1 (Table 1).
One mcPV cohort (mcPV11–15) includes patients with
mcPV who had autoantibodies to Dsg3 in the absence of
autoantibodies to Dsg1 at the time of the blood draw. The
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Figure 3. Expression of hDsg3 rescues the mDsg3KO phenotype. (a) Clinical phenotype and (b) weights (in grams) of mDsg3KO, WT, and hDsg3Tg mice are
shown at 21 days of age. (c) Histology of the mDsg3KO, WT, and hDsg3Tg buccal mucosa is shown (original magniﬁcation × 200). Bar = 100 μm. Dsg,
desmoglein; hDsg3, human Dsg3; KO, knockout; mDsg3, murine Dsg3.
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second mcPV cohort (mcPV16–20) includes patients with
strong recognition of IgG and IgG4 to both Dsg3 and Dsg1
(Table 1).
Using hDsg3Tg and WT palate as substrate, the sera of
these patients were tested by indirect IF. As IgG4 is known to
be pathogenic in PV, an anti-human IgG4 secondary antibody
was used for detection. As shown in Figure 4a, mPV patient
sera preferentially bind to the ICS of the hDsg3Tg palate
compared with the WT palate. Similarly, mcPV patients with
autoantibodies to Dsg3, but without autoantibodies to Dsg1,
preferentially recognize hDsg3 as well (mcPV11 shown).
Differential recognition of hDsg3 and mDsg3 by the sera
from mcPV patients with anti-Dsg3 and anti-Dsg1 is not
possible by indirect IF because of the additional presence of
autoantibodies to Dsg1, which are also detected by this
method. Therefore, immunoprecipitation was used as a
secondary method to conﬁrm preferential recognition of
mPV IgG to hDsg3 and to assess differential recognition of
hDsg3 and mDsg3 by mcPV IgG. Sera from all mPV patients
and mcPV with anti-Dsg3 alone (mcPV11–15) were able to
immunoprecipitate hDsg3, whereas only some sera were able
to precipitate mDsg3 (Figure 4b). Sera from mcPV patients
with both anti-Dsg3 and anti-Dsg1 (mcPV16–20) were able to
immunoprecipitate both hDsg3 and mDsg3, although two
patients (mcPV17 and mcPV20) also preferentially
recognized hDsg3.
IgG from mPV patients is pathogenic in hDsg3Tg mice
As mPV sera preferentially recognize hDsg3 expressed in the
mucosa of hDsg3Tg mice, we sought to assess pathogenicity
of mPV IgG by passive transfer. IgG puriﬁed from mPV
patients (mPV2 and 4) as well as mcPV11 was passively
transferred via submucosal injection to WT and hDsg3Tg
mice at amounts ranging from 1 to 8 mg of IgG. These sera
were chosen as they had high titers of autoantibodies by
indirect IF and large volumes available. At 18–20 hours post
transfer, the sera of both WT and hDsg3Tg recipients both
show detectable circulating human IgG by indirect IF on
monkey esophagus substrate with equivalent titers (1:40–
1:320), conﬁrming successful and equivalent passive transfer
of IgG (Figure 5d). However, only hDsg3Tg recipients showed
clinical mucosal erosions (Figure 5a), positive direct IF with
ICS deposition of human IgG4 in mucosal tissues (Figure 5b),
and acantholysis with suprabasilar clefting on histology
(Figure 5c). WT recipients had normal-appearing mucosa
and no evidence of acantholysis or suprabasilar clefting on
histologic examination. Direct IF was negative in WT
recipients despite the presence of circulating human auto-
antibodies in the sera. Clinical and histologic features of PV
following passive transfer were dose dependent, with more
severe disease being induced when recipient mouse sera
reached higher indirect IF titers. ICS deposition of human IgG
was detected in the basal layer and hair follicles of recipient
mice, but no cutaneous erosions or hair loss was noted on
examination. Histology of the skin of recipient mice showed
no evidence of acantholysis or clefting (data not shown). The
data are summarized in Supplementary Table S1 online.
DISCUSSION
The clinical distinction between mPV and mcPV has long
been noted and described by clinicians (Lever, 1965).
Autoantibody proﬁles against Dsg1 and Dsg3 have revealed
that mPV patients have autoantibodies to Dsg3, whereas
mcPV patients have autoantibodies to both Dsg3 and Dsg1
(Ding et al., 1997; Ishii et al., 1997; Amagai et al., 1999b).
Indeed, progression from mPV to mcPV is accompanied by
the acquisition of autoantibodies to Dsg1 (Ding et al., 1997;
Ishii et al., 1997; Miyagawa et al., 1999; Amagai et al.,
1999b). Early studies conﬁrmed that afﬁnity-puriﬁed anti-
Dsg1 and anti-Dsg3 autoantibodies from mcPV patients are
independently pathogenic upon passive transfer to neonatal
mice (Ding et al., 1999). However, IgG from mPV that harbor
antibodies to Dsg3 alone is nonpathogenic in the neonatal
Table 1. Characteristics of PV patient sera
Clinical phenotype1
Indirect IF titers2 ELISA index values3
IgG IgG4
Dsg3 Dsg1
IgG IgG4 IgG IgG4
mPV
mPV1 1:640 1:320 124.6 72.3 8.8 0.8
mPV2 1:640 1:320 122.9 157.6 3.0 0.2
mPV3 1:640 1:320 108.4 125.9 6.9 0.8
mPV4 1:320 1:320 100.0 100.0 3.8 0.5
mPV5 1:640 1:40 58.3 31.7 2.6 2.0
mPV6 1:160 1:40 67.9 50.8 6.2 0.9
mPV7 1:320 1:160 43.7 38.0 5.6 0.3
mPV8 1:160 1:80 40.8 50.7 2.9 0.9
mPV9 1:160 1:40 41.0 43.2 2.6 1.3
mPV10 1:320 1:40 13.9 4.8 1.9 0.2
mcPV with antibodies to Dsg3 only
mcPV11 1:640 1:640 130.7 193.0 1.6 0.3
mcPV12 1:1280 1:640 82.8 71.8 3.4 0.1
mcPV13 1:160 1:160 43.6 72.3 3.7 1.1
mcPV14 1:320 1:160 14.3 2.8 5.4 0.2
mcPV15 1:320 1:40 28.6 20.9 1.3 0.6
mcPV with antibodies to Dsg3 and Dsg1
mcPV16 1:1280 1:640 139.7 259.9 114.0 144.9
mcPV17 1:640 1:160 111.2 97.3 30.5 32.7
mcPV18 1:640 1:160 96.0 90.5 31.8 15.7
mcPV19 1:320 1:320 81.2 117.6 50.6 66.8
mcPV20 1:640 1:160 42.7 34.6 21.7 10.4
Abbreviations: Dsg3, desmoglein 3; IF, immunoﬂuorescence; mPV,
mucosa pemphigus vulgaris; mcPV. mucocutaneous pemphigus vulgaris.
1Patients were selected on the basis of their clinical phenotype and
divided into three cohorts: mPV, mcPV with anti-Dsg3 antibodies but
lacking anti-Dsg1 antibodies, and mcPV with both anti-Dsg3 and anti-
Dsg1 antibodies.
2Indirect IF titers as tested on monkey esophagus substrate.
3ELISA results are reported as index values.
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passive transfer model because of lack of mDsg3 reactivity
(Ding et al., 1997). Mahoney et al. described similar ﬁndings
and attribute the lack of mPV IgG pathogenicity to differential
expression patterns of Dsg1 and Dsg3 in the skin and oral
mucosa of humans and mice (Mahoney et al., 1999). Even
at very high doses (up to 26mg IgG per pup) IgG from PV
sera with anti-Dsg3 autoantibodies alone is unable to
induce blister formation in murine neonatal skin or mucosa
upon passive transfer (Mahoney et al., 1999). Little
progress has been made in the understanding of mPV IgG
pathogenicity and the immunological basis of the transition of
mPV to mcPV since these initial studies over 15 years ago.
We show here that mPV IgG with autoantibodies to Dsg3 is
pathogenic in vivo, but require the expression of hDsg3.
These ﬁndings conﬁrm that the pathogenic epitopes recog-
nized by most mPV anti-Dsg3 autoantibodies are speciﬁc to
hDsg3. Transfer of fairly low doses (1–8mg per mouse) of
mPV IgG into adult submucosa is sufﬁcient to induce classic
IgG ICS deposition and suprabasilar acantholysis and clefting
in hDsg3Tg, but not WT mucosa. Clinical and histologic
features of PV following passive transfer are dose dependent,
with more severe disease induced when higher titers are
reached. Dsg1 and Dsc3 expression patterns are similar in
hDsg3Tg and WT tissues, further validating this animal model.
Studies to demonstrate similar Dsc1 expression have not been
performed in this animal model, and therefore it is possible
that hDsg3 insertion inﬂuences Dsc1 expression, which could
have an impact on epidermal adhesion.
Although mPV IgG was able to efﬁciently induce mucosal
lesions in hDsg3Tg animals, there was no evidence of skin
lesions in the recipient mice. As mentioned previously,
afﬁnity-puriﬁed anti-Dsg3 autoantibodies from mcPV patients
do recognize mDsg3 and are able to induce skin lesions
upon neonatal passive transfer (Ding et al., 1999), although
neonatal mucosal tissues were not examined in the study.
These ﬁndings suggest that, whereas most mPV IgG
preferentially recognize hDsg3-speciﬁc epitopes, mcPV anti-
Dsg3 autoantibodies are able to recognize pathogenic
epitopes shared by mDsg3 and hDsg3. This idea is further
supported by our data, whereby mcPV patients with both anti-
Dsg3 and anti-Dsg1 autoantibodies are able to immunopre-
cipitate mDsg3. We speculate that PV patients with initial
mucosal disease may harbor autoantibodies that preferentially
recognize hDsg3-speciﬁc epitopes and that through intramo-
lecular epitope spread, upon transition to mcPV, develop
autoantibodies to additional Dsg3 epitopes that are shared by
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Figure 4. Sera from mPV patients preferentially recognize hDsg3. Sera from well-characterized mPV and mcPV patients were tested by indirect IF (a) using WT
and hDsg3Tg mucosa with anti-human IgG4 FITC as the secondary antibody. Healthy control sera (Neg) and pemphigus foliaceus (PF) sera are included as
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same gel are indicated by a white dashed line. Bar= 25 μm. hDsg3, human desmoglein 3; HRP, horseradish peroxidase; IF, immunoﬂuorescence; KO, knockout;
mDsg3, murine desmoglein 3; mPV, mucosa pemphigus vulgaris; mcPV, mucocutaneous pemphigus vulgaris; WT, wild type.
DA Culton et al.
mPV IgG Are Pathogenic in Humanized Dsg3 Mice
1594 Journal of Investigative Dermatology (2015), Volume 135
hDsg3 and mDsg3 in addition to developing anti-Dsg1
autoantibodies. It is interesting that two mPV patients (mPV6
and mPV8) recognize hDsg3 and mDsg3 to a similar degree
by immunoprecipitation, suggesting they may be in the
earliest stages of transition to mcPV. Similarly, two mcPV
patients (mcPV17 and mcPV20) preferentially recognize
hDsg3. Clinically, mcPV17 had recalcitrant mucosal lesions
throughout the course of disease. We speculate that differ-
ential epitope recognition over the disease course may play a
role in clinical phenotypes. Additional studies are required to
explore this intriguing possibility. There is a high degree of
homology between hDsg3 and mDsg3, particularly in the
extracellular domains 1 and 2, which are felt to harbor
pathogenic epitopes (Futei et al., 2000). The implication of
these data is that there are relatively few amino acid residues
responsible for the preferential binding of mPV to hDsg3.
As recent studies have shown that initial mucosal-only
involvement is a prognostic factor for achieving complete
remission off therapy, understanding and potentially halting
the progression of mPV to mcPV could have important
clinical implications. This hDsg3 murine model will be of
great value in further exploring autoantibodies in mPV and the
transition from mPV to mcPV.
MATERIALS AND METHODS
Generation of hDsg3 mice
The BAC clone RP11-1123B14 was obtained from Children’s Hospital
Oakland Research Institute. The hDsg3 BAC includes the entire hDsg3
gene sequence with approximately 57 kb 5′ and 30 kb 3′ of the Dsg3
sequence. The hDsg3 BAC was microinjected into B6D2 embryos
following standard pronuclear microinjection techniques (Nagy et al.,
2003). Resulting animals were genotyped with 6 primer sets speciﬁc for
human DNA regions spaced approximately every 20 kb across the
BAC. Founders that included the entire BAC were each bred to a WT
(B6 background) animal. Resulting offspring were screened for the
presence of the BAC using genomic DNA from tail snips and the
aforementioned primers. Offspring carrying the BAC
(hDsg3TgmDsg3WT/WT) were crossed to mDsg3 knockout hetero-
zygotes (hDsg3NegmDsg3WT/KO) obtained from Jackson Laboratories
(Bar Harbor, ME). The F1 generation yielded hDsg3TgmDsg3WT/KO,
which were backcrossed to B6 for three additional generations (total
four backcrosses to B6). Crossing of the resultant hDsg3TgmDsg3WT/KO
and hDsg3NegmDsg3WT/KO produced littermates of multiple genotypes
including hDsg3TgmDsg3KO/KO (fully hDsg3, termed hDsg3Tg),
hDsg3NegmDsg3WT/WT (WT), and hDsg3NegmDsg3KO/KO (Dsg3 KO)
mice. The breeding strategy is shown in Supplementary Figure S1
online. Genotyping was performed on genomic DNA from tail snips
using hDsg3 BAC–speciﬁc as well as mDsg3 WT and KO allele–
speciﬁc primers. Primers are listed in Supplementary Table S2 online.
All animal experiments were approved by the University of North
Carolina Institutional Animal Care and Use Committee.
Histology and IF studies
Tissues were harvested from adult mice 6–8 weeks of age. Formalin-
ﬁxed, parafﬁn-embedded sections were processed by hematoxylin
and eosin staining for histologic evaluation by a board-certiﬁed
dermatopathologist blinded to the specimen genotype.
For IF studies, tissue was embedded, frozen in optimal cutting
temperature embedding media, and cryosections prepared. Anti-
mouse Dsg3 (clones AK18 and AK23, MBL, Woburn, MA) and anti-
hDsg3 (clone 5G11, AbD serotec, Oxford, UK) antibodies diluted in
Tris-buffered saline 5mM Ca++ (tris-buffered saline/Ca++) were
applied to the sections in a humidity chamber at room temperature
for 30 minutes. Following three 10 minute washes, polyclonal goat
anti-mouse IgG-H+L-FITC (Abcam, Cambridge, MA) was used as a
secondary antibody before evaluation under a ﬂuorescence scope.
Anti-mouse Dsc3 (gp2280, the kind gift of Dr Peter Koch) was used to
detect Dsc3 as above, but with a primary overnight incubation at 4 °
C followed by goat anti–guinea pig Alexa 488 (Life Technologies,
Grand Island, NY). Similar studies were performed using patient sera,
followed by mouse anti-human IgG4 FITC (clone HP-6025, Sigma, St
Louis, MO) as a secondary antibody. For direct IF studies,
cryosections were directly stained with anti-human IgG4 FITC (clone
HP-6025, Sigma).
WT hDsg3Tg
Figure 5. IgG from mPV patients induce acantholysis in hDsg3Tg mucosa
upon passive transfer. Mucosal tissues from hDsg3Tg mice show clinical
erosions (a), positive direct IF with anti-human IgG4 FITC (b, Bar = 25 μm),
and histology with suprabasilar clefting and acantholysis (original
magniﬁcation × 100; c, Bar = 100 μm) as compared with WT mucosal tissues.
Both WT and hDsg3Tg sera show positive indirect IF (d, Bar = 25 μm)
with equivalent titers (1:80) on the monkey esophagus substrate
conﬁrming successful passive transfer. hDsg3, human desmoglein 3; IF,
immunoﬂuorescence; mPV, mucosa pemphigus vulgaris; WT, wild type.
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Protein extraction and western blotting
Whole tissue extracts were prepared by homogenizing murine
mucosal tissues in 2% SDS/β-mercaptoethanol lysis buffer on ice.
Extracted protein was quantiﬁed and equal amounts were subjected
to SDS-PAGE and transferred to polyvinylidene diﬂuoride membrane.
Membranes were blocked for 1 hour in 5% fat-free milk, 0.1%
Tween-20-tris-buffered saline. Following three 10-min washes in
0.1% Tween-20-tris-buffered saline, membranes were incubated
overnight with anti-mouse-Dsg3 antibody (clone AK18, MBL,
Woburn, MA) and anti-human-Dsg3 antibody (clone 5G11, AbD
serotec). The membranes were washed, incubated for 1 hour with
goat anti-mouse IgG-HRP (R&D Systems, Minneapolis, MN), and
developed using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientiﬁc, Rockford, IL).
Sources of sera
Sera were collected from patients at the autoimmune blister-
ing disorder clinic with disease conﬁrmed by clinical, histo-
logical, and immunoﬂuorescent ﬁndings. Control sera were
obtained from the University of North Carolina Blood Bank.
The study was approved by the University of North Carolina
Institutional Review Board and conducted according to the Declara-
tion of Helsinki Principles. Participants gave their written informed
consent.
Construction and production of recombinant hDsg1, hDsg3,
and mDsg3
We have previously constructed and expressed the entire extra-
cellular domains of hDsg1 and Dsg3 using the baculovirus system
(Ding et al., 1997, 1999; Flores et al., 2012). The mDsg3 DNA
plasmid pEVmod-murineDsg3-His (kind gift of Dr Masayuki Amagai,
Keio University, Tokyo, Japan) was used to generate the mDsg3
recombinant baculovirus using the BacPAK Baculovirus Expression
System (Clontech, Mountain View, CA). Soluble ectodomains of
hDsg1, hDsg3, and mDsg3 were produced in the baculovirus system
and puriﬁed by nickel chromatography as described (Flores et al.,
2012).
ELISA
Immunomicrotiter plates (Costar, Cambridge, MA) were coated with
puriﬁed hDsg3 or Dsg1 at 4 °C overnight. IgG and IgG4 ELISA was
then performed as described (Qaqish et al., 2009; Flores et al., 2012).
Results were expressed as index values (Amagai et al., 1999a; Diaz
et al., 2008; Flores et al., 2012).
Immunoprecipitation
Initial chessboard titration experiments were performed to determine
the optimal amount of hDsg3 and mDsg3 supernatant with
equivalent his-tagged recombinant protein levels to be incubated
with 2 ul of known positive and negative control sera. The sera and
culture supernatant containing hDsg3 or mDsg3 were incubated
overnight and immunoprecipitated as described (Li et al., 2003).
The precipitated protein was then subjected to SDS-PAGE,
transferred, probed with anti-His-HRP (Penta-his HRP, Qiagen,
Hilden, Germany), and developed using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientiﬁc, Rockford, IL).
Passive transfer of mPV IgG
IgG from mPV sera was puriﬁed using HiTrap Protein G HP columns
(GE Healthcare Life Sciences) and concentrated using Amicon Ultra
Centrifugal Filters (Millipore, Billerica, MA). Puriﬁed, concentrated
IgG was quantiﬁed and transferred submucosally to 6-week-old
hDsg3Tg or WT mice. Doses ranged from 1 to 8mg of total IgG per
mouse. Mice were killed and tissues harvested at 18–20 hours and
processed for routine histology and direct IF using mouse anti-human
IgG4 FITC (clone HP-6025, Sigma). Sera of recipient mice were also
harvested for indirect IF studies as described above.
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